Get the Stockscreener App
20.20
3.11%
0.61
Cidara Therapeutics Inc Stock (CDTX) Latest News
RA CAPITAL MANAGEMENT, L.P. Increases Stake in Cidara Therapeuti - GuruFocus.com
Cidara Therapeutics announces $105 million private placement By Investing.com - Investing.com South Africa
Cidara Therapeutics announces $105 million private placement - Investing.com India
Cidara: Potential To Change Flu Prophylaxis Landscape With CD388 - Seeking Alpha
Cidara to raise up to $105 million in private placement - The Pharma Letter
Cidara Therapeutics Shares Surge 26% on $105 Mln Private Placement - MarketWatch
Cidara Therapeutics Announces $105 Million Private Placement - GlobeNewswire
Cidara Therapeutics Secures $105M Private Placement Led by Venrock Healthcare | CDTX Stock News - StockTitan
Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference - GlobeNewswire
Cidara Therapeutics CEO to Present at Evercore HealthCONx Conference | CDTX Stock News - StockTitan
(CDTX) Technical Data - Stock Traders Daily
HC Wainwright Has Positive Outlook of CDTX FY2024 Earnings - MarketBeat
Cidara Therapeutics (NASDAQ:CDTX) Given Buy Rating at HC Wainwright - MarketBeat
Analysts Set Cidara Therapeutics, Inc. (NASDAQ:CDTX) PT at $29.67 - MarketBeat
Cidara Therapeutics (NASDAQ:CDTX) Now Covered by Guggenheim - MarketBeat
Cidara Therapeutics: Q3 Earnings Snapshot - Houston Chronicle
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - GlobeNewswire
Cidara's Q3 Loss Widens to $16M Despite Strong CD388 Trial Progress and Cash Position | CDTX Stock News - StockTitan
(CDTX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Will Rezafungin Trial Data ReSTORE Investors' Faith In Cidara? - RTTNews
Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences - GlobeNewswire
How Cidara Got Its Molecule Back - BioProcess Online
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Significant Drop in Short Interest - MarketBeat
Cidara Therapeutics, Inc. (CDTX) Stock Price & Chart | Trade Now - Capital.com
Cidara Therapeutics (NASDAQ:CDTX) Receives “Buy” Rating from HC Wainwright - Defense World
Cidara Therapeutics (NASDAQ:CDTX) Receives Buy Rating from HC Wainwright - MarketBeat
Cidara Therapeutics (NASDAQ:CDTX) Stock Price Passes Below Fifty Day Moving AverageWhat's Next? - MarketBeat
Cidara Therapeutics Announces Two Presentations on Drug-Fc Conjugate, CD388, at IDWeek 2024 - GlobeNewswire
(CDTX) Investment Analysis and Advice - Stock Traders Daily
Influenza Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Invasive Fungal Infection Market 2034 | Key Brands -Cidara Therapeutics, Basilea Pharmaceutica, Pfizer, GlaxoSmithKline, – IndiaPolitics.com - IndiaPolitics.com
(CDTX) On The My Stocks Page - Stock Traders Daily
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com
Shattuck Labs stock craters following pipeline and job cuts - Pharmaceutical Technology
Cidara Therapeutics Announces Two Presentations on - GlobeNewswire
Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference - StockTitan
How to Take Advantage of moves in (CDTX) - Stock Traders Daily
Long-acting Antiviral for Pre-exposure Protection Against Influenza Launches Phase 2b Study - Precision Vaccinations
Cidara Therapeutics begins phase 2b trial for flu prophylaxis By Investing.com - Investing.com Australia
Adverum Biotechnologies (NASDAQ:ADVM) & CRISPR Therapeutics (NASDAQ:CRSP) Head to Head Comparison - Defense World
Cidara starts Phase 2b trial of influenza drug CD388 By Investing.com - Investing.com Canada
Codexis, Inc. (NASDAQ:CDXS) Major Shareholder Opaleye Management Inc. Purchases 45,000 Shares - Defense World
Cadence Design Systems Inc. stock rises Monday, still underperforms market - MarketWatch
Xponance Inc. Has $24.15 Million Holdings in Cadence Design Systems, Inc. (NASDAQ:CDNS) - Defense World
Cidara Therapeutics begins phase 2b trial for flu prophylaxis - Investing.com India
CTXR’s price-to-book ratio: An indicator of the company’s performance - US Post News
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):